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Immunotherapy holds great promise in overcoming the limitations of conventional
regimens for cancer therapeutics. There is growing interest among researchers and
clinicians to develop novel immune-strategies for cancer diagnosis and treatment with
better specificity and lesser adversity. Immunomodulation-based cancer therapies are
rapidly emerging as an alternative approach that employs the host’s own defense
mechanisms to recognize and selectively eliminate cancerous cells. Recent advances
in nanotechnology have pioneered a revolution in the field of cancer therapy. Several
nanomaterials (NMs) have been utilized to surmount the challenges of conventional anti-
cancer treatments like cytotoxic chemotherapy, radiation, and surgery. NMs offer a
plethora of exceptional features such as a large surface area to volume ratio, effective
loading, and controlled release of active drugs, tunable dimensions, and high stability.
Moreover, they also possess the inherent property of interacting with living cells and
altering the immune responses. However, the interaction between NMs and the immune
system can give rise to unanticipated adverse reactions such as inflammation, necrosis,
and hypersensitivity. Therefore, to ensure a successful and safe clinical application of
immunomodulatory nanomaterials, it is imperative to acquire in-depth knowledge and a
clear understanding of the complex nature of the interactions between NMs and the
immune system. This review is aimed at providing an overview of the recent developments,
achievements, and challenges in the application of immunomodulatory nanomaterials
(iNMs) for cancer therapeutics with a focus on elucidating the mechanisms involved in the
interplay between NMs and the host’s immune system.
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INTRODUCTION
The emergence of cancer and its advancement are manifestations of the inadequacy of the host’s
immune system to recognize and execute an effective response to the tumor antigens. The cells of the
host’s immune system are responsible for distinguishing and eliminating the cancer cells during the
immune surveillance process (Houghton, 1994; de Visser et al., 2006; Lakshmi Narendra et al., 2013).
Tumor cells escape the immunosurveillance by evading the anti-tumor measures of the immune
system (Liu and Cao, 2016; Muenst et al., 2016). Tumor-derived signals within the tumor
microenvironment (TME) downregulates the anti-cancer functions of the infiltrating immune
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cells. Moreover, they are modulated to promote tumor growth
and progression (Whiteside, 2008; Lei et al., 2020). Thus, the
immune system plays a paradoxical role by creating an
immunosuppressive microenvironment that facilitates cancer
progression (de Visser et al., 2006; Kitamura et al., 2015).
Immunosuppression can be defined as the diminished ability
of the body to induce an immune response due to a lack of
immune cells such as T and/or B lymphocytes (Lakshmi
Narendra et al., 2013) (For definitions refer Glossary).
Chemotherapy is a common treatment for several types of
cancers; however, this form of therapy often leads to
immunosuppression due to a decrease in the population of
immune cells such as T and B lymphocytes (Muenst et al.,
2016), and dendritic cells (DCs) (Ferrari et al., 2003; Wertel
et al., 2007). However, several chemotherapeutic agents are
reported to weaken the immune system by inhibiting the
production of blood cells at the bone marrow, resulting in a
drastic decrease in the total cell count and impaired immunity
(Peng et al., 2015; Liu and Cao, 2016; Muenst et al., 2016).
Traditional strategies to combat cancer include cytotoxic
chemotherapy, radiation therapy, and surgical interventions.
Besides having several adverse side-effects, these approaches
also lack the cardinal ability to specifically target the cancer
cells while causing minimum damage to healthy cells (Chircop
and Speidel, 2014; Pearce et al., 2017). Deleterious side-effects,
immunosuppression, multi-drug resistance, and lack of
specificity of the existing treatments have necessitated
exploration into alternative therapies for cancer. Recently,
there has been a paradigm shift in cancer therapeutics towards
alternate immunotherapies (Kazemi et al., 2016).
Immunotherapy involves enhancing or suppressing the host’s
immune system for the treatment of disease without the
utilization of cytotoxic drugs. When applied for cancer
treatment, the goal of cancer immunotherapy is to harness the
inherent ability of the host’s immune system to eradicate cancer
cells in a minimally invasive manner without causing serious side
effects, unlike its conventional counterparts (Restifo et al., 2012).
There is growing interest among researchers and clinicians aimed
at developing novel strategies with better specificity in targeting
cancer cells while instigating the least amount of adverse
reactions. Recently, some of the alternate approaches to treat
cancer are based on immunomodulation which employs the
host’s own natural defense mechanisms to recognize and
selectively eliminate the cancer cells by inducing the immune
system (Liu, Z. et al., 2018; Tan et al., 2017; Zhang et al., 2016).
Immunomodulation is the process of altering the immune system
and its responses. This readjustment of the immune system can
either occur naturally, as a part of homeostatic regulation or it can
be induced bymedical intervention to achieve a therapeutic effect.
Besides, this regulation process can be assistive or suppressive in
nature to either amplify or abate the immune responses,
respectively. In recent years, the technique of induced
immunomodulation has gained popularity as a tool for cancer
therapeutics.
Nanomaterials can be defined as a class of materials that
possess at least one dimension within the range of 1–100 nm
(Bleeker et al., 2013). Advances in the field of nanotechnology and
material sciences have opened new avenues in the synthesis and
development of various nanomaterials (NMs composed of DNA,
organic/inorganic polymers, carbon, metals, liposomes, etc. for
cancer therapy. The nanostructures can be fabricated in various
shapes, sizes, and along with versatile surface functionalities.
NMs, when introduced in vivo, are recognized by the immune
cells as foreign entities therefore generate an immune response
that can either be immunostimulatory or immunosuppressive
(Yoshioka et al., 2017; Feng et al., 2019). While for most of the
applications, these effects are undesirable, but in the case of
cancer immunotherapy, the unique immunomodulatory action
of NMs can be exploited to target cancer cells.
Recent advances in the field of nanomaterial fabrication and
their functionalization has led to the emergence of a new class of
multifunctional nanotherapeutic materials that have the potential
to revolutionize the field of cancer therapy (Roy Chowdhury et al.,
2016). These nanotherapeutic agents exploit several unique
properties of NMs such as their ability to specifically target
cancer cells, localize at the tumor site, stay in circulation for a
longer time period by avoiding clearance, encapsulate and co-
deliver multiple active agents, the stimuli-responsive release of
cargo, et cetera (Baetke et al., 2015; Chen et al., 2017). Moreover,
NM based cancer therapeutic strategies hold great promise for
application of personalized medicine as targeted cancer
treatments (Diou et al., 2012; Jo et al., 2016).
Interestingly, recent breakthroughs in cancer therapeutics
have been for NMs such as gold nanostructures, carbon dots,
and carbon nanotubes which possess the ability to cross the
blood-brain barrier (BBB). This unique property of NMs creates
an opportunity to deliver therapeutic and imaging agents across
the BBB and has stimulated widespread research in exploiting
their application in brain-cancer treatment and diagnostics (Tang
et al., 2019). Additionally, attractive properties of nanoparticles
such as a large surface area to volume ratio, tunable dimensions,
and, high stability have also imparted beneficial features to the
cancer therapeutic regimens. The ability of porous and hollow
nanoparticles to load hydrophobic cancer drugs as cargo, protect
them from degradation and delivery at the target site in a
controlled manner, have revolutionized the designing of cancer
nanomedicines (Qin et al., 2017). NMs offer a dual aspect of
immunomodulation therapies. They can themselves act as
immunomodulatory agents by interacting with the immune
system after administration or they can merely act as delivery
platforms for targeted delivery of other immunomodulating
agents (Kubackova et al., 2020).
The immunomodulatory action of NMs can have positive as
well as negative impacts (Figure 1). Therefore, the need of the
moment is to acquire in-depth knowledge and a clear
understanding of the interactions between NMs and the
immune system. These insights are vital for the safe
application of immunomodulatory nanomaterials (iNMs) for
cancer therapeutic applications. In this review, we have
focused on the immunomodulatory effects of various NMs
and their application towards cancer therapy. The article
highlights the role of the immune system in cancer and the
interaction of NMs with the immune system to target and
eliminate cancer cells either actively or passively. The recent
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advances in iNMs and their application in cancer therapy are also
discussed with a focus on elucidating their mode of action to
achieve a better understanding of the nanomaterial-immune
system interactions.
IMMUNE SYSTEM AND CANCER
The Immune System
Immunity can be defined as the inherent ability of an organism to
avert pathogens and diseases by recognition and subsequent
neutralization or elimination of foreign entities by the
organism’s immune system. These protective mechanisms
involve various organs, tissues, cells, and chemical mediators
of the immune system and are largely based on the ability to
differentiate between the “self ” and “non-self ”. The innate
(natural) and the adaptive (acquired) immunity are the two
major components of the immune system that orchestrate the
overall immune responses against foreign pathogens and
transformed cells. Therefore, functions of the immune system
along with the immune cells acts as a defense barrier against a
plethora of invading pathogens as well as cancer in order to
restore and maintain homeostasis (Parkin and Cohen, 2001).
Innate immunity consists of pre-deployed molecular and
cellular barriers that act against the pathogen within hours of
initial contact and therefore serve as the first line of defense of the
immune system. Physical barriers include skin, mucosal linings,
hair, cilia, etc. that serve as the first line of defense of the immune
system. When these physical barriers are breached, the protective
role of the soluble mediators and the effectors of the innate system
comes into play. The chemical barriers consist of chemical agents
present in the antimicrobial peptides, lysozyme, gastric
secretions, glandular secretions, small intestine, and blood.
Various cell types such as phagocytes (e.g., macrophages,
neutrophils, dendritic (DC) cells), and leukocytes (e.g., natural
killer (NK) cells, mast cells, eosinophils, basophils) also
participate in the innate immune responses as a second line of
defense. Another important innate cellular population is that of
keratinocytes which are actively involved in recognizing and
responding to the pathogen-associated molecular patterns
(PAMPs) present on pathogens and danger molecules such as
damaged-associated molecular patterns (DAMPs) expressed by
the abnormal host cells (Moser and Leo, 2010; Takeuchi and
Akira, 2010). Upon recognition by the pattern recognition
receptors (PRRs) and subsequent activation of the
keratinocytes, cascades involving the release of various soluble
mediators (e.g., cytokines, chemokines, complement proteins,
collectins, etc.) and antimicrobial peptides (e.g., histatins,
cathelicidins, defensins, etc.) are initiated. Therefore, soluble
mediators, antimicrobial peptides, and cellular receptors (e.g.
Toll-like receptors) are an integral part of the innate immunity
that recognizes and responds to the chemical makeup of the
pathogens (Braff and Gallo, 2006; Coates et al., 2018). The
barriers and the cells of the innate system are the first to
encounter and respond to an antigen. Such responses lack
specificity but act as a fast and effective primary response
against foreign particles (Turvey and Broide, 2010; Iwasaki
and Medzhitov, 2015). Moreover, the innate immune system
also plays a crucial role in activating the subsequent adaptive
immune responses.
On the contrary, the adaptive immune responses are not
immediate; they take several days to develop but are highly
specific in neutralizing the antigen. Such responses serve as
the third line of defense and are acquired by the host’s
immune system after encountering an antigen. The T and B
lymphocytes orchestrate the two key features of the host’s
adaptive immune responses; 1) The vast and specific range of
T and B cell receptors generated via the process of somatic
recombination, and; 2) The ability to develop immunological
“memory” upon encountering pathogens leading to a more rapid
and potent immune response in case of subsequent encounters
(Bonilla and Oettgen, 2010). The cell-mediated adaptive
immunity involves cytotoxic T cells that can recognize affected
cells and induce cell death (Wing and Remington, 1977). The
humoral adaptive immunity is established by helper T cells via
activation of B cells which produce specific antibodies against the
FIGURE 1 | Nanomaterial-mediated immunomodulation for cancer therapeutics.
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pathogen. The barriers of adaptive immunity include lymph
nodes, lymphoid tissues, and the spleen. The random
generation of a wide range of antigen receptors via somatic
recombination confers the adaptive immune system with the
diverse ability to recognize a plethora of pathogens. However, this
diversity comes at a price and can often lead to ineffectiveness in
distinguishing between the self and non-self and subsequent
attack on the host’s own cells giving rise to autoimmune
diseases. Consequently, the immune system has several
mechanisms and checkpoints in place for recognition,
regulation, and elimination of self-reactive immune cells.
Another unique feature of adaptive immunity is the ability to
generate custom-tailored antigen-specific T and B lymphocytes
upon initial encounter with the pathogen. This ensures a potent
and highly specific immune response that is effective in
neutralization or elimination of the pathogen. Unfortunately,
the process takes a significant period of time (5–6 days)
leading to a considerable delay in the elicitation of the
adaptive immune responses (Tomar and De, 2014).
In the context of the evolutionary timeline, innate immunity
was developed earlier and therefore is found in all multicellular
living beings. Whereas, adaptive immunity was an outcome of
subsequent evolutionary processes and thus is present only in
higher vertebrates (Pancer and Cooper, 2006). Therefore, rather
than clear distinct systems, there exists an intertwined network of
regulatory mechanisms between the two systems and the overall
host defense is a result of a highly complex crosstalk and
coordination between the innate and adaptive immunity
(Cooper, 2016; Symowski and Voehringer, 2017). Certain cells,
proteins, and receptors such as NK cells (Fehniger et al., 2003;
Sun and Lanier, 2009), DCs (Palucka and Banchereau, 1999;
Chan et al., 2006), cytokines (Belardelli and Ferrantini, 2002;
Schön and Erpenbeck, 2018), Toll-like Receptors (TLRs) (Pasare
and Medzhitov, 2004), platelets (Elzey et al., 2003; Elzey et al.,
2005), are involved in this crosstalk by acting as crucial links
between the innate and adaptive immune systems.
Besides acting as a defense barrier against pathogens and
eliminating/neutralizing foreign antigens, the immune system
also plays an important role in maintaining tolerance towards
self and clearing abnormal or damaged host cells that can lead to
cancer and various autoimmune disorders (Knochelmann et al.,
2018). A diseased condition arises when the immune system is
either 1) weak or inactive (immunodeficiency); 2) overactive
(hypersensitivity); 3) loses the inherent capacity to distinguish
between self and non-self which results in an immune attack
towards the host itself (autoimmunity); and/or 4) the antigen/
pathogen evades all the existing immune defenses of the host’s
immune system leading to the manifestation of the disease
(infection) (Kelly and Leonard, 2003; Martinon and Tschopp,
2004; Finlay and McFadden, 2006; Gregersen and Behrens, 2006;
Valenta et al., 2009). As the functions of the immune system are
impaired in such diseases, positive or negative modulation of the
immune responses by activating or suppressing the immune
system with the help of immunomodulatory agents serves as
an effective mode of treatment. Immuno-suppressive therapies
and anti-inflammatory agents are common treatments for
diseases related to autoimmunity, inflammation, or
hypersensitivities (Ephrem et al., 2005; Broide, 2009; Musette
and Bouaziz, 2018; Immunotherapies for Autoimmune Diseases,
2019). Similarly, in the case of immune-deficiencies, upregulation
of immune responses via immuno-stimulatory therapies have
shown promising outcomes. Immunostimulatory treatments are
also effective in treating bacterial and viral infections (Drews,
1980; Dickneite et al., 1984; Smalley Rumfield et al., 2020).
Recently, studies are being conducted towards the application
of immunomodulation therapies in combating severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
in patients suffering from coronavirus disease 2019 (COVID-
19) (Hall et al., 2020; Ingraham et al., 2020; Tay et al., 2020).
These therapies are aimed at enhancing the patient’s innate and
adaptive immune mechanisms to overcome the pathogenesis of
SARS-CoV-2. Additionally, several in vivo studies have
demonstrated that an impaired immune system leads to higher
incidences of clinical manifestations leading to malignant tumors
suggesting the importance of immunosurveillance by the immune
system in preventing cancer (Shankaran et al., 2001). Therefore,
the immune system and its modulation play a critical role in
oncogenesis as well as its treatment.
Role of Immune System in Cancer
Cancer cells can be categorized as altered host cells that evade the
growth regulation mechanisms, override the homeostasis
maintenance pathways, and undergo uncontrolled growth (Li
and Neaves, 2006). The cellular components and biochemical
mediators of both innate and adaptive immunity are involved in a
complex crosstalk to give rise to an effective anti-tumor response
consisting of processes such as immunoediting and the cancer
immunity cycle (Swann and Smyth, 2007; Calì et al., 2017).
Adaptive immunity is responsible for the generation of
antigen-specific immune responses; hence, it plays a central
role in eliciting anti-cancer responses against the cancer tumor
antigens.
Anti-Cancer Measures by the Immune System
The host’s immune system coordinates a highly complex series of
sequential steps to eliminate the cancer cells. These events lead to
the development of effective anti-cancer responses which
altogether constitute the “cancer immunity cycle” (Chen and
Mellman, 2013). During the early stages of cancer development,
the tumor/cancer immunity is established when tumor antigens are
recognized by dendritic cells (DCs) of the host’s immune system
and the antigens are processed and presented on the surface of
antigen-presenting cells (APCs) via major histocompatibility
complex (MHC) I or II. DC cells are a crucial link between
innate and adaptive immunity and orchestrate the response to
antigen by processing and presenting it to the cells of the adaptive
immune system. They are responsible for priming and activating
the naïve T cells located within the draining lymph nodes (DLNs)
via interaction with MHC complex and co-stimulatory signals.
This leads to the maturation of T cells to effector T cells that
overexpress certain receptors. Regulatory T cells (Tregs) play a key
role in modulation of the immune system to maintain tolerance
towards self-antigens. Tregs have immunosuppressive effects as
they usually downregulate the functioning of T effector cells.
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Studies have shown that the depletion of the Tregs population at
the tumor site helps to overcome the immunosuppressive TME
and significantly improves the efficacy of cancer
immunotherapies (Curiel, 2007; Wang et al., 2017). Once
activated, the circulating T effector (Te) cells reach the tumor
site and are responsible for evoking an immune response against
the cancerous cells. The cytotoxic T lymphocytes (CTLs)
recognize tumor cells via MHC-I and eliminate them by
releasing chemical cues such as granzyme B and perforins.
The macrophages and mast cells release soluble chemical
mediators such as cytokines, histamine, chemokines, and
reactive oxygen species (ROS) when they encounter the
tumor antigen. The chemical mediators initiate inflammation
and tissue repair. The obliteration of tumor cells, in turn,
releases more tumor-derived antigens that lead to the
establishment of a more robust cancer-immunity. Therefore,
the key players in establishing an effect on tumor immunity are
macrophages, DCs, cytotoxic T lymphocytes (CTLs), and
regulatory (Tregs) T cells (Chen and Mellman, 2017).
Additionally, for specific and effective elimination of
cancerous cells, the activity of CTLs and macrophages should
be stimulated while the function of Tregs inhibited (Ruter et al.,
2009).
Recognition and Elimination by the Immune System
Cancer immunoediting comprises of three phases (Dunn et al.,
2004). The first is the elimination phase which involves
immunosurveillance by the innate and adaptive immune
systems to detect and eliminate the abnormal cells that are
either malignant or have the potential to become malignant.
The elimination phase involves several cell populations such as
NK cells, macrophages, DCs, cytotoxic T cells, and B cells (Dunn
et al., 2006). This stage marks the undetectable phase of early
tumor development. The tumor cells that have escaped the initial
stage of elimination enter the next phase of equilibrium where the
tumor cells coexist with the host’s immune system. This is the
longest phase and marks a temporary state of equilibrium
between the host’s immune system and the tumor. Moreover,
during this period, the tumor cells can either remain dormant or
can accumulate mutations giving rise to new tumor variants that
in turn increases the overall resistance of the tumor to the host’s
immune mechanisms (Mittal et al., 2014). The growth and
expansion of tumor cells may eventually lead to the escape
phase where the cancer cells can metastasize and give rise to
malignancies (Dunn et al., 2002; Smyth et al., 2006).
Escape and Evasion by the Tumor Cells
As the tumor growth progresses, some of the tumor cells may
evade the immune system’s measures and escape. Most of the
evasion mechanisms of the tumor cells facilitate the development
of a TME that can protect the cancer cells by suppressing the
host’s immune responses (Schreiber et al., 2011). Therefore,
immunoediting is a continuous process involving both
immunosurveillance to eliminate cancer cells and the evasion
by tumor cells that leads to tumor progression. The escape of
tumor cells from various stages of immunoediting is mediated by
numerous immunosuppressive strategies. Some of these evading
mechanisms include downregulation or absence of MHC class I
expression on cancer cells preventing T cell-mediated responses,
production of cytokines that induce anti-apoptotic pathways,
upregulation of non-classical MHC class I expression
preventing NK mediated cell killing and tumor cell-induced
immunosuppression (Waldhauer and Steinle, 2008; Al-
Tameemi et al., 2012; Mohme et al., 2017). Escape and evasion
of tumor cells often leads to cancer malignancies, creating the
need for clinical interventions in the form of various cancer
therapies.
Emergence of Cancer Immunotherapies
Cancer is one of the major causes of death around the world.
Figure 2 depicts the prevalence of cancer and cancer-related
mortalities across major countries based on the latest Globocan
2020 report. In the year 2020 alone, cancer was responsible for
approximately 9.9 million deaths globally out of which about 65%
of the deaths were attributed to under-developed and developing
countries (Figure 2 (inset)).
The conventional cancer treatments are based on surgical
intervention, radiation therapy, and/or chemotherapy. Even
though these procedures are highly invasive and involve
deleterious side-effects, they constitute a major part of the
standard cancer treatment methodology (Cosentino and Piro,
2018; Pusuluri et al., 2019). These treatments are applied either
individually or in combination to combat cancer and its
recurrence. However, these conventional methods of treatment
are associated with several limitations such as poor solubility due
to the hydrophobic nature of the drug, lack of selectivity and
specificity, immunosuppression, multidrug resistance, high rate
of metastasis and recurrence. These limitations have encouraged
the development of alternative therapies based on modulation of
the immune system and its responses to better combat cancer
either independently or in conjugation with the conventional
treatments.
The therapeutic method based on modulating the host’s own
immune system to eliminate cancer was first proposed in the early
1890s (Coley, 1991). Unfortunately, the novel technique failed to
draw the attention of the oncologists due to the lack of knowledge
and understanding of the underlying mechanisms of the immune
system. Consequently, over the new few decades, a treatment plan
consisting of conventional procedures such as surgery, radiation
and/or chemotherapy prevailed as a gold standard for treating
cancer.
However, simultaneously the following decades saw a steady
rise in the number of studies aimed at unravelling the intrinsic
relation between the immune system and cancer (Figures 3, 4).
Along the path, a vast knowledge has been gathered by
elucidating the role of the host’s immune cells in establishing
anti-tumour responses and the evading mechanisms of the cancer
cells. The in-depth understanding of the immune mechanisms
and the severe limitations of conventional cancer treatments led
to the revival of the immunomodulatory approach towards
combating cancer (D’Errico et al., 2017; Decker and Safdar 2009).
As a result, in the early 2000s, the concept of immunotherapy
was revisited as an alternative approach to treat cancer (Zacharski
and Sukhatme, 2005). Unlike the traditional treatments, these
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therapies are based on boosting the host’s immune responses by
administering cytokines, antibodies and/or various co-
stimulatory signals. Therefore, they have fewer side-effects and
are much more effective in eradicating primary tumours and
preventing future incidences of recurrence and metastasis
(Kroemer and Zitvogel, 2018). Thus, immunotherapy served as
a cornerstone for a paradigm shift in the battle against cancer and
has become a standard part of the cancer treatment regimen
FIGURE 2 | Cases of cancer prevalence and mortality in the year 2020. In inset: Estimation of mortalities due to cancer in 2020 among countries based on human
development index (HDI). Statistics provided by Globocan 2020, World Health Organization.
FIGURE 3 | Year-wise number of publications on ’Immune system’ and ’Cancer’ from the year 1945–2019. As per the data available on PubMed.
FIGURE 4 | Number of publications on “Nanomaterial mediated immunomodulation” and “Immunomodulatory cancer therapeutics” indexed in PubMed from year
1998–2019.
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(Abbott and Ustoyev, 2019). Till today, several cancer
immunotherapies have been developed based on stimulation of
DCs (e.g. DC-based vaccines) (Sabado et al., 2017; Perez and De
Palma, 2019), enhancing the T-cell mediated immune responses
(e.g. Adoptive T-cell therapy and chimeric antigen receptor
(CAR) T-cell therapy) (Met et al., 2019; Miliotou and
Papadopoulou, 2018) and by blocking the inhibitory
checkpoints that suppress the immune responses towards
cancer (e.g. Checkpoint inhibitor therapy) (Ribas and
Wolchok, 2018; Xu, W. et al., 2020). In 2018, the Nobel Prize
in Physiology or Medicine was awarded to James P. Allison and
Tasuku Honjo for their ground-breaking work on cancer
immunotherapy via inhibition of negative regulation (Ballas,
2018). Despite the novel approach of cancer immunotherapy
techniques, the extent of their clinical applications has been
largely restricted due to significant limitations. For example,
cancer patients undergoing checkpoint-inhibition
immunotherapies are often prone to developing immune-
related adverse events and autoimmune diseases (Dhodapkar,
2019; Pauken et al., 2019). Cancer immunotherapies have shown
limited effectiveness in the treatment of solid tumours due to the
inability of the immune cells to infiltrate the solid tumour and its
microenvironment (Melero et al., 2014). Only a fraction of cancer
patients responds to administered immunotherapies and the ones
who respond often develop acquired resistance to these therapies
(Draghi et al., 2019; Hegde and Chen, 2020). Moreover, certain
tumours are characterized as “cold” due to the lack of infiltrating
T cells indicating the presence of an immunosuppressive TME
that discourages immune activation (Bonaventura et al., 2019).
Such “cold” tumours act as a major challenge as they show poor
response towards traditional cancer immunotherapies. Thus,
much of cancer research has been focused on turning these
“cold” tumours into “hot” tumours by modulating the TME
and boosting the host’s immune system (Duan et al., 2020).
The technological advances in the field of nanotechnology
hold a great promise towards the development of better-targeted
cancer immunotherapies with higher specificity, stability, and
sustained antitumour effects (Shukla and Steinmetz, 2016). Due
to their small size, NMs can effectively infiltrate solid tumours,
display retention properties, escape clearance, remain in
circulation for longer periods and their surfaces can be easily
functionalized to bear specific targeting moieties (Liu, Y. et al.,
2018). They can also be applied as nano-delivery systems that can
encapsulate various small active agents and deliver them in a
sustained manner at the target site (Sarkar et al., 2013; Asadi et al.,
2017). When compared to their free forms, the NM encapsulated
formulations of several drugs have shown better toxicity profiles
with lesser side-effects upon administration thereby significantly
improving the therapeutic index of these potent drugs (Desai
et al., 2006; Fukuda et al., 2017).
In recent times, several cancer immunotherapies have been
aimed at targeting the stages of the cancer immunity cycle. The
latest advances in this research area include the application
of nanomaterials for formulating improved cancer
immunotherapies to achieve enhanced tumor-targeting and
neutralizing the immuno-suppressive TME (Yang and Zhang,
2020). A recent work involving the fabrication of a three-in-one
nanoplatform was successful in amplifying the various phases of
the cancer-immunity cycle to boost the overall immune responses
against cancer antigens. The immunotherapy was based on NM-
mediated delivery of an immune-agent to elicit a robust immune
action along with memory responses. Therefore, it acted as a
potent nano-weapon for the prevention of tumor metastasis and
future relapses (Li Q. et al., 2019). Another interesting study
based on liposomal co-delivery of imatinib (IMT) and siRNA-
PD-L1 showed promising results towards enhancement of the
cancer immunity cycle by knockdown of programmed cell death
ligand 1 (PD-L1) which in turn prevented the PDL1-mediated
immunosuppression of tumor-specific CTLs (Li and Han, 2020).
Nanoparticles can infiltrate the “cold” tumours allowing co-
delivery of a wide variety of payloads specifically to the tumour
site thus boosting the immune activation at TME. Additionally,
the immunomodulatory properties of the NMs also aid in turning
“cold” tumours into “hot” (Rodallec et al., 2018; Buabeid et al.,
2020). For example, a recent study based on citrate-coated
superparamagnetic iron oxide NPs (SPIONs) display the
capacity to act as a magnetic drug delivery system for guided
targeting to “cold” tumours by application of an external
magnetic field (Mühlberger et al., 2019). The application of
NMs in cancer immunotherapies has opened new arenas to
integrate therapy and diagnosis into a single nano-therapeutic
unit, leading to a paradigm shift in onco-treatments and paving
way for novel developments in the field of cancer therapy and
diagnosis (Tan et al., 2020). Another recent interesting study was
based on the utilization of a zeolitic imidazole framework (ZIF) as
a nanoplatform for pH-responsive release of cargo molecules for
targeted combinational therapy to treat “cold” tumours. The
nanoplatform was loaded with a photothermal agent
(indocyanine green) and an immune adjuvant (imiquimod).
The multifunctional nanoplatform eradicated the primary
tumours in in vivo tumour models and also prevented tumour
recurrence when re-challenged (Yu et al., 2020). Since the success
of any immunotherapy-based cancer therapy depends largely on
enhancing the inherent cancer immunity of the patient, a
comprehensive understanding of the underlying mechanisms
of immunomodulation is an essential pre-requisite for
designing an efficient clinical strategy.
IMMUNOMODULATION AS A TOOL IN
CANCER THERAPEUTICS
Immunomodulation is the process of altering the immune system
and its responses. Such alteration can be of two types: immuno-
suppression–where the immune responses are diminished or
immuno-stimulation–where the immune responses are amplified
(Grabowski et al., 2020; Nishiguchi and Taguchi, 2020). This fine-
tuning of the immune system can either occur naturally, as a part of
homeostatic regulation or it can be induced by medical
interventions to achieve a therapeutic effect. Immunosuppressive
therapies are usually applied in the case of auto-immune diseases
(Carballido et al., 2020) and immuno-stimulation is a course of
action for cancer and infectious diseases (Dittmer and Olbrich,
2003; García-Martínez et al., 2018). The recent trend is to apply
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nanotechnology to design alternative treatment approaches which
can induce therapeutic effects at the target site while causing
minimum collateral damage and adverse effects (Li, T. et al.,
2020; Tan et al., 2020). Unlike conventional cancer therapies,
this approach provides a more precise and personalized
therapeutic effect that causes minimum side-effects and allows
simultaneous imaging of the target site (monitoring)
(Hapuarachchige and Artemov, 2020; Xu, C. M. et al., 2020). As
a result, the technique of induced immunomodulation has gained
popularity as a tool for cancer therapy (Comparetti et al., 2018; Li,
J. et al., 2019; Xu, B. et al., 2020). Since these immunotherapy-based
approaches towards eradicating cancer cells rely on employing the
body’s own natural defense system to combat cancer they achieve
targeted results with fewer side-effects than conventional cancer
treatments (Sau et al., 2019).
NMs have gained a lot of attention in the field of biomedical
and therapeutics due to several unique set of features offered by
this class of smart materials. These properties of NMs are
discussed in detail in the following Properties of
Nanomaterials (NMs) Section of this article. Over recent
years, several types of NMs have been investigated for their
ability to react with components of the immune system and
modulate its behavior. The modulation of the immune system via
nanomaterials is a complex process and can have both beneficial
and harmful effects (Alsaleh and Brown, 2018). Also, the
nanomaterial-mediated immunomodulation can be achieved
either directly- where the NMs itself causes
immunomodulatory effects or indirectly- where the NMs acts
as a vehicle for targeted delivery of immunomodulatory agents
(IMAs) (Bartneck, 2017; Kubackova et al., 2020). Moreover, due
to the small size of NMs and the leaky vasculature of tumors, the
NMs undergo enhanced permeability and retention (EPR) effects
that allow them to access tumors and selectively co-localize
within them (Shi et al., 2020). Therefore, nanomaterial-
mediated immunomodulation has the ability to execute
targeted delivery of cargo molecules to the immune cells,
resulting in better clinical outcomes with minimal adverse
events. These unique properties have resulted in a fast-
growing interest in the field of NM-mediated





Over the last few decades, advancements in the field of
nanotechnology and material sciences have led to a major
breakthrough in the fabrication of various NMs composed of
DNA (Dai et al., 2017; Jiang et al., 2017), polymers (Chang
et al., 2018; Simpson et al., 2019), carbon (Teradal and Jelinek,
2017; Jiang et al., 2019), metals (Dhivya et al., 2015; Singh,
2018), composites (Song et al., 2015; Zhai et al., 2018),
liposomes (Zhang et al., 2011; Lorente et al., 2018; Zhang
et al., 2018), et cetera for cancer therapy. Synthesis of NMs
allows the materials to be fine-tuned to tailor their properties
(e.g., size, composition, surface properties, etc.) according to
the targeted biological application (Wang et al., 2009). The
NMs within the dimension range of 1–100 nm closely resemble
the natural hierarchy and architecture of human cells, tissues,
and ECM at a nanoscale. This confers NMs with the ability to
interact with their surroundings, improving the effectiveness,
accuracy, and efficacy of the nanomaterial-mediated
therapeutic and diagnostic approaches (Li, B. et al., 2018;
Tan and Saltzman, 2004). Additionally, attractive properties
of NMs such as a large surface area to volume ratio, tunable
dimensions, ease of surface functionalization, and, high
stability have also imparted beneficial features to the cancer
therapeutic regimens (Sun et al., 2014). Various works have
also reported conferring “stealth” properties to nanomaterials
by attachment of surface molecules such as polyethylene glycol
(PEG) (Suk et al., 2016) and CD47 molecules (Gheibi Hayat
et al., 2019) to prolong their systemic circulation time by
delaying in vivo clearance (Fam et al., 2020). A recent study
on the fabrication of nano-artificial antigen-presenting cells
(aAPCs) decorated with both PEG and CD47 moieties have
shown evasion of nanoparticles to phagocytic clearance along
with their ability to induce the generation of antigen-specific
T cells to suppress tumour development (Song et al., 2019).
Another promising feature of NMs towards drug delivery
applications is the ability to easily functionalize their
surfaces with various ligands to improve cellular uptake and
achieve a highly specific targeted drug delivery (Cisterna et al.,
2016; Sykes et al., 2016).
Due to the enhanced surface area to volume ratio, the porous
and hollow nanomaterials display excellent drug loading
efficiencies (Yang et al., 2019). Such NMs are capable of
efficiently encapsulating the hydrophobic (water-insoluble)
cancer drugs as cargo within their framework, thereby
improving the stability of drug molecules, protecting them
from degradation, improving their bioavailability, and
delivering them to the target site in a controlled manner
(Kashi et al., 2012). The delivery of therapeutic agents (TAs)
conjugated within nanomaterials also increases their circulation
time, allows cellular- and/or tissue-specific targeting, and a
stimuli-responsive controlled release of TAs at the target site.
These factors drastically reduce the adverse effects of the TAs on
the nearby cells and tissues (Iglesias et al., 2018). For instance, in
the past decade, mesoporous silica nanoparticles (MSNs) have
been exploited as stimuli-responsive nano-carriers for targeted
delivery of a wide range of small molecules for diagnostic as well
as therapeutic approaches. Major advantages of using MSN-type
nano-systems for delivery of cytotoxic cancer drugs are improved
drug efficacy, stimuli-responsive controlled release at the target
site, and reduced toxic effects to nearby healthy tissues (Alyassin
et al., 2020; Aquib et al., 2019; Li, T. et al., 2019; Nguyen et al.,
2019). Another area of recent breakthroughs in cancer
therapeutics has been in the field of NMs [such as gold
nanostructures (Cheng et al., 2014; Lee et al., 2017), carbon
dots (Li et al., 2016; Liyanage et al., 2020), carbon nanotubes
(You et al., 2019), liposomes (Vieira and Gamarra, 2016; Jena
et al., 2020), etc.] that possess the ability to cross the blood-brain
barrier (BBB). This unique property of such NMs creates an
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opportunity to deliver therapeutic and imaging agents across the
BBB and has stimulated widespread research in exploiting their
application in brain-cancer treatment and diagnostics (Tang
et al., 2019). Recently, an in vivo study conducted in mice has
reported the first successful application of a polymeric nano-
immuno-conjugate to deliver immune-therapeutics across BBB
and stimulation of local antitumour immune response for the
treatment of glioma tumours (Galstyan et al., 2019).
However, the adverse effects associated with the delivery of
cytotoxic agents along with the increased chances of drug
resistance largely overshadow the therapeutic effects of such
an approach (Weber et al., 2015; Babiker et al., 2018; Makovec,
2019). This has led to the emergence of a much efficient
treatment regimen for the eradication of tumours involving
modifying the body’s own immune responses towards the
tumour cells (Irvine et al., 2013). As described in the
previous section, such immunomodulatory therapies are
aimed at converting immunosuppressive TME into an
immunostimulatory one, facilitating the elimination of cancer
cells. This also leads to the generation of memory T-cells against
cancer antigens thereby discouraging incidences of metastasis
and future relapses (Curti et al., 2013; Locy et al., 2018).
Consequently, recent works in the area of cancer therapeutics
have been majorly focused on utilizing various biomolecules
and nanomaterials to increase the specificity and efficacy of
direct and/or indirect immunomodulation (Chidambaram et al.,
2011). NMs have the potential to be utilized as a delivery system
that allows in vivo imaging, sustained cargo release, enhanced
circulation time, targeted delivery, and stimuli-responsive
release of cargo molecules and multiple agents (Li, L. et al.,
2018).
Interaction of NMsWith the Immune System
The in-depth knowledge about the components of the immune
system and their role in regulating numerous diseases when
combined with the recent technological advancement in the
field of fabrication of safe and biocompatible NMs have
revolutionized the biomedical applications of nanomaterials.
Nanomaterial-based therapies have been applied for the
treatment of autoimmune diseases (Gao et al., 2017;
Kwiatkowski et al., 2020), neurodegenerative diseases
(Fornaguera et al., 2015; Turjeman et al., 2015), inflammatory
diseases (Li, C. W. et al., 2020; Tran et al., 2015), and cancer (Xin
et al., 2017; Samanta et al., 2019). When introduced in vivo, NMs
act as foreign entities and consequently lead to various immune
responses. Nearly all the NMs exert immunomodulatory effects in
vivo which can be either immunostimulatory or
immunosuppressive in nature. The unique ability of NMs to
interact with components at a nanoscale and bring about change
can lead to both therapeutic as well as deleterious events. As a
result, in most of the biomedical applications, the modulatory
effects of NMs are undesirable as they often lead to adverse
effects. For instance, several recent in vitro and in vivo studies
have demonstrated the severe immunotoxicity associated with
the use of single-walled carbon nanotubes (SWCNTs) for
biomedical applications (Sayes et al., 2006; Tian et al., 2006;
Wang et al., 2011). The surface chemistry, concentration, density
of functionalization, and surface area of SWCNTs critically
influence their interaction with macrophages and the immune
organs such as the spleen (Sayes et al., 2006; Zhang et al., 2011;
Lee et al., 2015).
However, at times, the ability to modulate immune
responses by NMs have shown compelling results and
serves as a tool for immunomodulatory therapies.
Therefore, NMs have found a wide-scale application as a
tool to mediated immunomodulation either directly by
interacting with the components of the immune system or
indirectly by acting as a carrier for the delivery of
immunomodulatory agents. Recent studies based on NM-
mediated direct immunomodulation and NMs as a delivery
system for IM agents are listed in Supplementary Tables S1
and S2 (supplied as Supplementary Material), respectively.
NM MEDIATED DIRECT AND INDIRECT
IMMUNOMODULATION
A variety of immunomodulatory NMs with a unique plethora of
physical and chemical attributes have been fabricated for
stimulating the immune system to combat cancer. For
example, the distinctive ability of the platelets to target
cancer cells and their inherent capacity to load drug
molecules have been utilized to develop targeted drug
delivery nanosystems for anti-cancer therapies. Liposome-
based delivery systems are a popular platform for targeted
delivery and sustained release of anti-cancer agents
(Mukherjee et al., 2019). Various liposomal formulations
have been developed for the delivery of immunomodulatory
agents (IMAs) that allow modulation of the TME to establish an
overall antitumor immune response again tumour antigens
(Gilabert-Oriol et al., 2018). Recent studies have also
highlighted the inherent tendency of liposomes to interact
extensively with the immune system leading to several
immunomodulatory effects on the growth of the tumour (La-
Beck et al., 2019). Unique core-shell structure allows
simultaneous co-delivery of multiple cargo molecules, in vivo
protection against degradation and the facile surface chemistry
can be applied to decorate the NM surface with active targeting
moieties, thus making liposomes an excellent candidate for
cancer therapeutic applications.
Additionally, several bio-inspired NMs have also gained
popularity due to their enhanced biocompatibility and cyto-
friendly nature, eco-friendly mode of synthesis, superior
bioactivity when compared to the chemically synthesized NMs
(Mukherjee and Patra, 2017). Biosynthesized metallic
nanoparticles, especially gold (AuNPs) and silver (AgNPs)
have been widely studied for achieving targeted cancer therapy
and diagnosis (Balakrishnan et al., 2017; Mukherjee et al., 2015;
Mukherjee et al., 2016). For example, a study based on
biosynthesized colloidal AgNps prepared from leaf extract
showed enhanced antibacterial and anti-cancer activity than
the chemically synthesized NPs. The multifunctional AgNPs
were biocompatible and exhibited bright red fluorescence
upon intracellular localization emphasizing their potential to
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be utilized for biomedical diagnostic tools (Mukherjee et al.,
2014). Thus, immunomodulatory NMs possess unique and
tunable properties that hold great potential to be utilized as
cancer therapeutic agents.
CLINICAL STUDIES AND PERSPECTIVES
Regardless of the advantages of NMs, very few NM-based
immunomodulatory cancer therapies have been actively
translated to clinical application majorly due to the limited
knowledge about the behavior of NMs when introduced in
vivo and their long-term toxicity (Sun et al., 2019). The
unique properties of NMs, while being attractive for various
biomedical applications, at times also raise quite a few
biosafety concerns. For example, due to the surface properties
such as hydrophobicity and surface charge, NMs when
introduced in vivo tend to agglomerate into larger particles
that might lead to accumulation and toxicity (Pattan and
Kaul, 2014). Moreover, as a result of their small size, NMs
have the ability to penetrate cells and organelles. Several
studies have also shown an increase in intracellular oxidative
stress and damage when cells are exposed to NMs such as carbon
nanotubes (Francis and Devasena, 2018), gold nanoparticles
(Chen et al., 2009), copper nanoparticles (Meng et al., 2007),
titanium NMs (Demir, 2020), etc. These events often lead to
adverse effects such as DNA aberration, genetic instability and
inflammation depending upon the cell type, nature of NM and
material concentration (Demir, 2021).
Despite the limitations, some of the NM-based
immunomodulatory therapies that are undergoing clinical
trials hold immense potential towards a safe and successful
clinical application in cancer therapeutics. For example, a
recent human trial consisting of six patients suffering from
glioblastoma (GBM) involved the use of superparamagnetic
iron oxide nanoparticles (SPIONs) via the “NanoPaste”
technique. The resection cavities were coated with SPIONs
after which the patients were subjected to six sessions of
hyperthermia using alternating magnetic field lasting for about
1 h each. No major side-effects were observed during the ongoing
treatment. After 2–3 months of treatment, the imaging analysis
revealed the formation of NP deposits that displayed signs of
inflammation and edema. Further analysis indicated that the
treatment was effective in eliciting an antitumor response by
tumor necrosis, infiltration of macrophages following uptake of
NPs, increasing CD3+ T-cells, higher secretion of IFN-γ,
upregulated levels of Caspase-3, heat-shock protein 70, HLA-
DR, and PD-L1 within the tumor microenvironment (TME). Out
of the six patients, two showed prolonged therapeutic responses
(>23 months) without further therapies; however, four had to
undergo additional surgical procedures for removal of
accumulated SPIONs (Grauer et al., 2019).
Gadolinium-chelated polysiloxane based nanoparticles
(AGuIX) have shown promising results as a radiosensitizer
both in vitro (Mowat et al., 2011) and in vivo (Sancey et al.,
2015; Kotb et al., 2016). It has demonstrated great potential as
a theranostic agent for enhancing MRI contrast and as a
cytotoxic agent when conjugated with radiotherapy (Sancey
et al., 2014). These findings have motivated several clinical
studies for the safe application of these NPs in human cancer
patients (Lux et al., 2019). An ongoing NANO-RAD trial
(NCT02820454) utilizing gadolinium-chelated polysiloxane
based nanoparticles (AGuIX) as a theranostic as well as a
radiosensitizer agent has recently completed the recruitment
process. This phase I study will consist of about 15 participants
and is aimed at investigating the biosafety, dose tolerance, and
toxicology of the AGuIX NPs when applied in combination
with standard whole-brain radiotherapy (WBRT). The
administration of Nps will be done intravenously (IV)
followed by a magnetic resonance imaging (MRI) scan to
analyze the distribution of NPs. The patients will be
subjected to WBRT starting 4 h after IV administration,
5 days a week till 2 weeks of treatment. The
pharmacological studies of AGuIX Nps will be performed at
regular intervals by drawing blood from the patients. Phase II
of this trial (NANORAD2; NCT03818386) is also currently
under the recruitment stage. Another Phase II clinical trial to
evaluate the clinical impact of AGuIX in combination with
fractionated stereotactic radiotherapy (NANOSTEREO;
NCT04094077) is currently recruiting. Additionally, another
Phase I clinical trial (NANOCOL; NCT03308604) for patients
with locally advanced cervical cancer is currently in the
recruitment phase. The trial is based on evaluating the
biosafety and dosage tolerance of AGuIX NPs in
conjugation with radiation and cisplatin.
Another interesting research study (WDVAX; NCT01753089)
which is based on the formulation of a personalized melanoma
vaccine is currently under Phase I of clinical trials. The vaccine
will contain tumor lysate obtained from the patient’s own
melanoma tumor cells combined with other
immunostimulatory agents such as CpG and granulocyte-
macrophage colony-stimulating factor (GM-CSF). These
components will be combined together in a polymeric
biomaterial scaffold consisting of PLGA. The trial consists of
23 participants with metastatic melanoma and is aimed at
establishing the biosafety and efficacy of the scaffold-based
vaccine in modulating the patient’s own immune system to
build effective antitumor responses against the melanoma
tumor cells (Dolgin, 2013; Singh and Peppas, 2014).
Since, proteins and the immune cells are the first to
encounter NMs upon administration into an in vivo
biological system, therefore, prior to any clinical
application, it is essential to critically assess the nature of
interactions of NMs with the cells and the proteins of the living
system so as to ensure that the benefits outweigh the
limitations of any NM-based clinical therapy. However,
majority of the present clinical trials tend to emphasize
only on the therapeutic aspect of the NM-based treatments
while leaving out the biosafety concerns involved. Also, there is
a dire need to develop a unified and standardized procedure for
determining the biosafety of NMs during research and the
clinical studies in order to minimize adverse effects during
human trials and ensuring that more and more NM-based
therapies successfully attain clinical translation.
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CONCLUSION
Immunomodulation based cancer therapies rely on altering the
body’s own defenses to fight back and eradicate its enemy,
cancer. The targeted therapeutic effect in minimal
concentrations while causing minimum/no side-effects is the
major reason for the success of this approach. However, due to
the heterogeneous cellular composition of tumors, individual
cancer therapies, especially the ones based on conventional
approaches like surgery, radiation, and chemotherapy have
shown limited success. When used in isolation, these
treatments do not provide a curative measure for cancer.
Therefore, to enhance the efficacy of the treatment and
achieve better survivability, it is necessary to explore
combinatorial cancer therapies. The unintended and
unavoidable interactions of nanomaterials with the biological
systems including the immune system is a major hurdle for
tapping the optimum therapeutic effect. Due to this, only a
sparse number of immunotherapies have attained successful
clinical application. Thus, the future advancements in applying
immunomodulatory nanomaterials for cancer therapeutics
should be majorly focused on taking into consideration the
biosafety aspects of the use of nanomaterial. Additionally,
favorable aspect for the future cancer therapies will be based
on delivery of more than one active agent so as to accommodate
simultaneous diagnosis, targeting, treatment and monitoring.
Such immunomodulatory-based cancer therapeutics will exhibit
many promising results and improve survivability when used in
conjugation with other techniques to create an effective anti-
cancer regimen. Another aspect for potential research in this
field can be towards achieving precisely targeted delivery and
stimuli-responsive release of immunomodulatory therapeutic
agents.
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GLOSSARY
Nanomaterials (NMs) NMs are a class of materials that possess at least
one dimension within the range of 1–100 nm
Immunity The inherent ability of an organism to avert pathogens and
diseases by recognition and subsequent neutralization or elimination of
foreign entities by the organism’s immune system
Immunomodulation The process of altering the host’s immune system
and its responses
Immuno-stimulation The process of enhancing the ability of the body
to evoke a strong and robust immune response against an antigen
Immuno-suppression The diminished ability of the body to induce an
immune response due to a lack of immune cells such as T and/or B
lymphocyte
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